Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19808496 | 0.82 | ALDH1A1 (0.53) | ALDH1A1KMT2AHSD17B10TSHREPHX2 | |
| SCHEMBL1160886 | 0.81 | ALDH1A1 (0.42) | ALDH1A1KMT2AHSD17B10TSHRHSD11B1 | |
| SCHEMBL10131885 | 0.80 | ALDH1A1 (0.41) | ALDH1A1KMT2AHSD17B10TSHRHSD11B1 | |
| Hydrochloric Acid SCHEMBL9948050 | 0.80 | ALDH1A1 (0.41) | ALDH1A1KMT2AHSD17B10TSHRHSD11B1 | |
| SCHEMBL19808700 | 0.79 | ALDH1A1 (0.40) | ALDH1A1KMT2AHSD17B10TSHRHSD11B1 | |
| SCHEMBL9948713 | 0.75 | HSD11B1 (0.42) | ALDH1A1HSD17B10TSHRHSD11B1EPHX2 | |
| SCHEMBL1161114 | 0.74 | ALDH1A1 (0.43) | ALDH1A1KMT2AHSD17B10TSHREPHX2 | |
| SCHEMBL13126731 | 0.73 | LMNA (0.34) | ALDH1A1EPHX2HTT | |
| SCHEMBL20724787 | 0.73 | LMNA (0.34) | ALDH1A1EPHX2HTT | |
| SCHEMBL13766697 | 0.70 | SMN1; SMN2 (0.46) | ALDH1A1KMT2ATSHRHSD11B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324265-B2 | Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | HSD17B1, HSD11B1, HSD3B1 | ALDH1A1 207/4885KMT2A 2803/4885HSD17B10 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.